Industry-leading foundation models, built with pathologists in-the-loop
Atlas 2 foundation model
Atlas 2 is the new pathology foundation model co-developed in collaboration with Mayo Clinic. It was engineered with a unique “pathologists in-the-loop” approach, ensuring that medical expertise was integrated at every stage of development. Atlas demonstrates industry-leading performance across 80 public benchmarks.
Why use a foundation model?
Atlas H&E-TME: AI-Powered Tumor Microenvironment Analysis Product Overview
Atlas H&E-TME provides detailed insights about the tumor microenvironment in H&E-stained whole slide images. It is powered by Atlas 2, a leading foundation model codeveloped by Aignostics and Mayo Clinic. Download this product overview to learn about capabilities, example outputs, and use cases.
AI-Driven Target Discovery in LUSC: Validating a Multi-Omics Platform Through Rediscovery of Known and Novel Biology
The Aignostics-Bayer Target ID Platform integrates multi-omics data with explainable AI to identify complex biological patterns and reveal novel therapeutic hypotheses for cancers that lack effective treatments. This LUSC case study validates the Platform's ability to stratify patients into distinct subgroups, recapitulate known cancer biology, and identify unique molecular signatures that could lead to the generation of novel therapeutic hypotheses.
A timeline of our foundation models
January 2024
Aignostics releases its first foundation model, RudolfV, which sets a new standard for performance as measured by public benchmarks.
January 2025
Aignostics announces Atlas, its first foundation model developed in collaboration with Mayo Clinic. As with RudolfV, Atlas sets a new standard for performance.
January 2026
Aignostics announces Atlas 2, their new model developed with Mayo Clinic, setting new standards for foundation models. Atlas 2 shows the highest average performance across 80 public benchmarks.
Future
Aignostics is building a range of research offerings with Atlas that are geared toward biopharma. In addition, Aignostics and Mayo Clinic are co-developing even more powerful foundation models that will unlock new products for researchers and clinicians.
